Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.
The project involved simulating a flight beyond low-Earth orbit, including the effects of long-term isolation with restricted communication and expedition resources ...